Rutger H. T. Koornstra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rutger H. T. Koornstra has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Anne Isabelle Juliette Arens
Department of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands
6 shared publications - Catharina Willemien Menke-Van der Houven van Oordt
Department of Medical Oncology, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
6 shared publications - Derk Jan A. de Groot
Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
6 shared publications - Elske C. Gootjes
Department of Medical Oncology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
6 shared publications - Emma Geertruida Elisabeth de Vries
Department of Medical Oncology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands
6 shared publications - Erik J. van Helden
Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands
6 shared publications
Latest Publications
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal Cancer
Supplementary Table 2: Mean percentage changes in volumetric and semi-quantitative FDG PET/CT parameters during treatment (baseline vs. on-treatment) Part 2
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal Cancer
Supplementary Table 2: Mean percentage changes in volumetric and semi-quantitative FDG PET/CT parameters during treatment (baseline vs. on-treatment) Part 2
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Data from Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal Cancer
Purpose:Anti-EGFR mAb therapy improves the clinical outcome of patients with metastatic colorectal cancer (mCRC). This study assessed the predictive value of early [18F]fluorodeoxyglucose ([18F]FDG) PET/CT after one anti-EGFR mAb treatment in patients with mCRC.Patients and Methods:The multicenter IMPACT-CRC study (NCT02117466) prospectively included patients with mCRC receiving second- or third-line anti-EGFR mAb monotherapy. Clinical benefit (complete/partial response or stable disease per RECIST version 1.1) was determined with CT at 8 weeks. [18F]FDG PET/CT scans were performed at baseline and before the second treatment cycle (2 weeks). Total lesion glycolysis (TLG) change was evaluated as a predictive biomarker for clinical benefit using a predetermined data-driven threshold.Results:In patients with RAS/BRAF wild-type left-sided mCRC, the clinical benefit rate was 92% (31% partial response, 61% stable disease), with a median progression-free survival of 5.7 months (95% CI, 5.2–10). Seventy-five patients, including those with right-sided mCRC, were eligible for metabolic response analysis. Patients with clinical benefit (n = 57) showed a mean decrease in sum TLG of 58% (SD = 19%), compared with 1.9% (SD = 36%) in those without clinical benefit (n = 18; P = 0.003). A threshold of <15% reduction in sum TLG had a 100% negative predictive value for clinical benefit. Metabolic responders exhibited longer progression-free survival than nonresponders [6.5 vs. 1.7 months (P < 0.001)].Conclusions:Selecting patients with left-sided RAS/BRAF wild-type mCRC resulted in a 92% clinical benefit rate from anti-EGFR mAb monotherapy. Early [18F]FDG PET/CT identified nonresponders with 100% accuracy, offering promising clinical utility when tumor mutational status is unavailable.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal Cancer
Purpose:Anti-EGFR mAb therapy improves the clinical outcome of patients with metastatic colorectal cancer (mCRC). This study assessed the predictive value of early [18F]fluorodeoxyglucose ([18F]FDG) PET/CT after one anti-EGFR mAb treatment in patients with mCRC.Patients and Methods:The multicenter IMPACT-CRC study (NCT02117466) prospectively included patients with mCRC receiving second- or third-line anti-EGFR mAb monotherapy. Clinical benefit (complete/partial response or stable disease per RECIST version 1.1) was determined with CT at 8 weeks. [18F]FDG PET/CT scans were performed at baseline and before the second treatment cycle (2 weeks). Total lesion glycolysis (TLG) change was evaluated as a predictive biomarker for clinical benefit using a predetermined data-driven threshold.Results:In patients with RAS/BRAF wild-type left-sided mCRC, the clinical benefit rate was 92% (31% partial response, 61% stable disease), with a median progression-free survival of 5.7 months (95% CI, 5.2–10). Seventy-five patients, including those with right-sided mCRC, were eligible for metabolic response analysis. Patients with clinical benefit (n = 57) showed a mean decrease in sum TLG of 58% (SD = 19%), compared with 1.9% (SD = 36%) in those without clinical benefit (n = 18; P = 0.003). A threshold of <15% reduction in sum TLG had a 100% negative predictive value for clinical benefit. Metabolic responders exhibited longer progression-free survival than nonresponders [6.5 vs. 1.7 months (P < 0.001)].Conclusions:Selecting patients with left-sided RAS/BRAF wild-type mCRC resulted in a 92% clinical benefit rate from anti-EGFR mAb monotherapy. Early [18F]FDG PET/CT identified nonresponders with 100% accuracy, offering promising clinical utility when tumor mutational status is unavailable.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal Cancer
Figure 1A: Change in sum TLG after 1 dose of anti-EGFR therapy versus PFS. Green dots indicate patients with and red dots patients without treatment benefit after CT evaluation part 1. Grey line at data driven cut-off of < -15% change in sumTLG Figure 1B ROC curve of change in sum TLG and treatment benefit part 1 (AUC 0.89) Figure 1C: Kaplan-Meier survival curve for PFS for metabolic non-responders (<15% decrease in sum TLG) versus metabolic responders (≥15% decrease in sumTLG) patients in part 1. Figure 1D: Kaplan-Meier survival curve for OS for metabolic non-responders (<15% decrease in sum TLG) versus metabolic responders (≥15% decrease in sumTLG) patients in part 1.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal Cancer
Figure 1A: Change in sum TLG after 1 dose of anti-EGFR therapy versus PFS. Green dots indicate patients with and red dots patients without treatment benefit after CT evaluation part 1. Grey line at data driven cut-off of < -15% change in sumTLG Figure 1B ROC curve of change in sum TLG and treatment benefit part 1 (AUC 0.89) Figure 1C: Kaplan-Meier survival curve for PFS for metabolic non-responders (<15% decrease in sum TLG) versus metabolic responders (≥15% decrease in sumTLG) patients in part 1. Figure 1D: Kaplan-Meier survival curve for OS for metabolic non-responders (<15% decrease in sum TLG) versus metabolic responders (≥15% decrease in sumTLG) patients in part 1.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal Cancer
Supplementary - Study Representativeness Table
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal Cancer
Supplementary - Study Representativeness Table
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data S1 from Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal Cancer
Figure 1E Change in sum TLG after 1 dose of anti-EGFR therapy versus PFS in months. Green dots indicate patients with and red dots patients without treatment benefit after CT evaluation part 2. Grey line at data driven cut-off (part 1) of -15% change in sumTLG Figure 1F: Kaplan-Meier survival curve for PFS for metabolic non-responders (<15% decrease in sum TLG) versus metabolic responders (≥15% decrease in sumTLG) for patients in part 2. Figure 1G: Kaplan-Meier survival curve for OS for metabolic non-responders (<15% decrease in sum TLG) versus metabolic responders (≥15% decrease in sumTLG) for patients in part 2.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S1 from Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal Cancer
Figure 1E Change in sum TLG after 1 dose of anti-EGFR therapy versus PFS in months. Green dots indicate patients with and red dots patients without treatment benefit after CT evaluation part 2. Grey line at data driven cut-off (part 1) of -15% change in sumTLG Figure 1F: Kaplan-Meier survival curve for PFS for metabolic non-responders (<15% decrease in sum TLG) versus metabolic responders (≥15% decrease in sumTLG) for patients in part 2. Figure 1G: Kaplan-Meier survival curve for OS for metabolic non-responders (<15% decrease in sum TLG) versus metabolic responders (≥15% decrease in sumTLG) for patients in part 2.
- 10 November 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (1) , 118-126
Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal Cancer
Purpose: Anti-EGFR mAb therapy improves the clinical outcome of patients with metastatic colorectal cancer (mCRC). This study assessed the predictive value of early [18F]fluorodeoxyglucose ([18F]FDG) PET/CT after one anti-EGFR mAb treatment in patients with mCRC. Patients and Methods: The multicenter IMPACT-CRC study (NCT02117466) prospectively included patients with mCRC receiving second- or third-line anti-EGFR mAb monotherapy. Clinical benefit (complete/partial response or stable disease per RECIST version 1.1) was determined with CT at 8 weeks. [18F]FDG PET/CT scans were performed at baseline and before the second treatment cycle (2 weeks). Total lesion glycolysis (TLG) change was evaluated as a predictive biomarker for clinical benefit using a predetermined data-driven threshold. Results: In patients with RAS/BRAF wild-type left-sided mCRC, the clinical benefit rate was 92% (31% partial response, 61% stable disease), with a median progression-free survival of 5.7 months (95% CI, 5.2–10). Seventy-five patients, including those with right-sided mCRC, were eligible for metabolic response analysis. Patients with clinical benefit (n = 57) showed a mean decrease in sum TLG of 58% (SD = 19%), compared with 1.9% (SD = 36%) in those without clinical benefit (n = 18; P = 0.003). A threshold of <15% reduction in sum TLG had a 100% negative predictive value for clinical benefit. Metabolic responders exhibited longer progression-free survival than nonresponders [6.5 vs. 1.7 months (P < 0.001)]. Conclusions: Selecting patients with left-sided RAS/BRAF wild-type mCRC resulted in a 92% clinical benefit rate from anti-EGFR mAb monotherapy. Early [18F]FDG PET/CT identified nonresponders with 100% accuracy, offering promising clinical utility when tumor mutational status is unavailable.
- 10 November 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (1) , 118-126
Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal Cancer
Purpose: Anti-EGFR mAb therapy improves the clinical outcome of patients with metastatic colorectal cancer (mCRC). This study assessed the predictive value of early [18F]fluorodeoxyglucose ([18F]FDG) PET/CT after one anti-EGFR mAb treatment in patients with mCRC. Patients and Methods: The multicenter IMPACT-CRC study (NCT02117466) prospectively included patients with mCRC receiving second- or third-line anti-EGFR mAb monotherapy. Clinical benefit (complete/partial response or stable disease per RECIST version 1.1) was determined with CT at 8 weeks. [18F]FDG PET/CT scans were performed at baseline and before the second treatment cycle (2 weeks). Total lesion glycolysis (TLG) change was evaluated as a predictive biomarker for clinical benefit using a predetermined data-driven threshold. Results: In patients with RAS/BRAF wild-type left-sided mCRC, the clinical benefit rate was 92% (31% partial response, 61% stable disease), with a median progression-free survival of 5.7 months (95% CI, 5.2–10). Seventy-five patients, including those with right-sided mCRC, were eligible for metabolic response analysis. Patients with clinical benefit (n = 57) showed a mean decrease in sum TLG of 58% (SD = 19%), compared with 1.9% (SD = 36%) in those without clinical benefit (n = 18; P = 0.003). A threshold of <15% reduction in sum TLG had a 100% negative predictive value for clinical benefit. Metabolic responders exhibited longer progression-free survival than nonresponders [6.5 vs. 1.7 months (P < 0.001)]. Conclusions: Selecting patients with left-sided RAS/BRAF wild-type mCRC resulted in a 92% clinical benefit rate from anti-EGFR mAb monotherapy. Early [18F]FDG PET/CT identified nonresponders with 100% accuracy, offering promising clinical utility when tumor mutational status is unavailable.
- Open Access
- 24 January 2020
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 69 (3) , 477-488
Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial
Background: Autologous dendritic cell (DC) vaccines can induce tumor-specific T cells, but their effect can be counteracted by immunosuppressive mechanisms. Cisplatin has shown immunomodulatory effects in vivo which may enhance efficacy of DC vaccination.Methods: This is a prospective, randomized, open-label phase 2 study (NCT02285413) including stage III and IV melanoma patients receiving 3 biweekly vaccinations of gp100 and tyrosinase mRNA-loaded monocyte-derived DCs with or without cisplatin. Primary objectives were to study immunogenicity and feasibility, and secondary objectives were to assess toxicity and survival.Results: Twenty-two stage III and 32 stage IV melanoma patients were analyzed. Antigen-specific CD8+T cells were found in 44% versus 67% and functional T cell responses in 28% versus 19% of skin-test infiltrating lymphocytes in patients receiving DC vaccination with and without cisplatin, respectively. Four patients stopped cisplatin because of toxicity and continued DC monotherapy. No therapy-related grade 3 or 4 adverse events occurred due to DC monotherapy. During combination therapy, one therapy-related grade 3 adverse event, decompensated heart failure due to fluid overload, occurred. The clinical outcome parameters did not clearly suggest significant differences.Conclusions: Combination of DC vaccination and cisplatin in melanoma patients is feasible and safe, but does not seem to result in more tumor-specific T cell responses or improved clinical outcome, when compared to DC vaccination monotherapy.
- 24 January 2020
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 69 (3) , 477-488
Open AccessAutologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial
Background: Autologous dendritic cell (DC) vaccines can induce tumor-specific T cells, but their effect can be counteracted by immunosuppressive mechanisms. Cisplatin has shown immunomodulatory effects in vivo which may enhance efficacy of DC vaccination.Methods: This is a prospective, randomized, open-label phase 2 study (NCT02285413) including stage III and IV melanoma patients receiving 3 biweekly vaccinations of gp100 and tyrosinase mRNA-loaded monocyte-derived DCs with or without cisplatin. Primary objectives were to study immunogenicity and feasibility, and secondary objectives were to assess toxicity and survival.Results: Twenty-two stage III and 32 stage IV melanoma patients were analyzed. Antigen-specific CD8+T cells were found in 44% versus 67% and functional T cell responses in 28% versus 19% of skin-test infiltrating lymphocytes in patients receiving DC vaccination with and without cisplatin, respectively. Four patients stopped cisplatin because of toxicity and continued DC monotherapy. No therapy-related grade 3 or 4 adverse events occurred due to DC monotherapy. During combination therapy, one therapy-related grade 3 adverse event, decompensated heart failure due to fluid overload, occurred. The clinical outcome parameters did not clearly suggest significant differences.Conclusions: Combination of DC vaccination and cisplatin in melanoma patients is feasible and safe, but does not seem to result in more tumor-specific T cell responses or improved clinical outcome, when compared to DC vaccination monotherapy.
- Open Access
- 1 January 2020
- Published by Taylor & Francis in OncoImmunology
- Vol. 9 (1) , 1738814
Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination
Vaccination with autologous dendritic cells (DC) loaded ex vivo with melanoma-associated antigens is currently being tested as an adjuvant treatment modality for resected locoregional metastatic (stage III) melanoma. Based on its mechanism of action, DC vaccination might potentiate the clinical efficacy of concurrent or sequential immune checkpoint inhibition (ICI). The purpose of this study was to determine the efficacy of ICI administered following recurrent disease during, or after, adjuvant DC vaccination. To this end, we retrospectively analyzed clinical responses of 51 melanoma patients with either irresectable stage III or stage IV disease treated with first- or second-line ICI following recurrence on adjuvant DC vaccination. Patients were analyzed according to the form of ICI administered: PD-1 inhibition monotherapy (nivolumab or pembrolizumab), ipilimumab monotherapy or combined treatment with ipilimumab and nivolumab. Treatment with first- or second-line PD-1 inhibition monotherapy after recurrence on adjuvant DC vaccination resulted in a response rate of 52%. In patients treated with ipilimumab monotherapy and ipilimumab-nivolumab response rates were 35% and 75%, respectively. In conclusion, ICI is effective in melanoma patients with recurrent disease on adjuvant DC vaccination.
- 1 January 2020
- Published by Taylor & Francis in OncoImmunology
- Vol. 9 (1) , 1738814
Open AccessResponse and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination
Vaccination with autologous dendritic cells (DC) loaded ex vivo with melanoma-associated antigens is currently being tested as an adjuvant treatment modality for resected locoregional metastatic (stage III) melanoma. Based on its mechanism of action, DC vaccination might potentiate the clinical efficacy of concurrent or sequential immune checkpoint inhibition (ICI). The purpose of this study was to determine the efficacy of ICI administered following recurrent disease during, or after, adjuvant DC vaccination. To this end, we retrospectively analyzed clinical responses of 51 melanoma patients with either irresectable stage III or stage IV disease treated with first- or second-line ICI following recurrence on adjuvant DC vaccination. Patients were analyzed according to the form of ICI administered: PD-1 inhibition monotherapy (nivolumab or pembrolizumab), ipilimumab monotherapy or combined treatment with ipilimumab and nivolumab. Treatment with first- or second-line PD-1 inhibition monotherapy after recurrence on adjuvant DC vaccination resulted in a response rate of 52%. In patients treated with ipilimumab monotherapy and ipilimumab-nivolumab response rates were 35% and 75%, respectively. In conclusion, ICI is effective in melanoma patients with recurrent disease on adjuvant DC vaccination.
- Open Access
Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?
The prognosis of patients with advanced melanoma has improved dramatically. However, the clinical outcomes of patients with highly elevated serum lactate dehydrogenase (LDH) remain very poor. The aim of this study was to explore whether patients with normalized LDH after targeted therapy could benefit from subsequent treatment with immune checkpoint inhibitors (ICI). Data from all patients with BRAF-mutant metastatic melanoma with a highly elevated serum LDH at baseline (≥2× upper limit of normal) receiving first-line targeted therapy between 2012 and 2019 in the Netherlands were collected. Patients were stratified according to response status to targeted therapy and change in LDH at start of subsequent treatment with ICI. Differences in overall survival (OS) between the subgroups were compared using log-rank tests. After a median follow-up of 35.1 months, median OS of the total study population (n = 360) was 4.9 months (95% CI 4.4–5.4). Of all patients receiving subsequent treatment with ICI (n = 113), survival from start of subsequent treatment was significantly longer in patients who had normalized LDH and were still responding to targeted therapy compared to those with LDH that remained elevated (median OS 24.7 vs. 1.1 months). Our study suggests that introducing ICI upon response to targeted therapy with normalization of LDH could be an effective strategy in obtaining long-term survival in advanced melanoma patients with initial highly elevated serum LDH.
Open AccessSwitching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?
The prognosis of patients with advanced melanoma has improved dramatically. However, the clinical outcomes of patients with highly elevated serum lactate dehydrogenase (LDH) remain very poor. The aim of this study was to explore whether patients with normalized LDH after targeted therapy could benefit from subsequent treatment with immune checkpoint inhibitors (ICI). Data from all patients with BRAF-mutant metastatic melanoma with a highly elevated serum LDH at baseline (≥2× upper limit of normal) receiving first-line targeted therapy between 2012 and 2019 in the Netherlands were collected. Patients were stratified according to response status to targeted therapy and change in LDH at start of subsequent treatment with ICI. Differences in overall survival (OS) between the subgroups were compared using log-rank tests. After a median follow-up of 35.1 months, median OS of the total study population (n = 360) was 4.9 months (95% CI 4.4–5.4). Of all patients receiving subsequent treatment with ICI (n = 113), survival from start of subsequent treatment was significantly longer in patients who had normalized LDH and were still responding to targeted therapy compared to those with LDH that remained elevated (median OS 24.7 vs. 1.1 months). Our study suggests that introducing ICI upon response to targeted therapy with normalization of LDH could be an effective strategy in obtaining long-term survival in advanced melanoma patients with initial highly elevated serum LDH.
- Open Access
Metastatic Uveal Melanoma: Treatment Strategies and Survival—Results from the Dutch Melanoma Treatment Registry
Uveal melanoma (UM) is the most common primary intraocular tumor in adults. Up to 50% of UM patients will develop metastases. We present data of 175 metastatic UM patients diagnosed in the Netherlands between July 2012 and March 2018. In our cohort, elevated lactate dehydrogenase level (LDH) is an important factor associated with poorer survival (Hazard Ratio (HR) 9.0, 95% Confidence Interval (CI) 5.63–14.35), and the presence of liver metastases is negatively associated with survival (HR 2.09, 95%CI 1.07–4.08). We used data from the nation-wide Dutch Melanoma Treatment Registry (DMTR) providing a complete overview of the location of metastases at time of stage IV disease. In 154 (88%) patients, the liver was affected, and only 3 patients were reported to have brain metastases. In 63 (36%) patients, mutation analysis was performed, showing a GNA11 mutation in 28.6% and a GNAQ mutation in 49.2% of the analyzed patients. In the absence of standard care of treatment options, metastatic UM patients are often directed to clinical trials. Patients participating in clinical trials are often subject to selection and usually do not represent the entire metastatic UM population. By using our nation-wide cohort, we are able to describe real-life treatment choices made in metastatic UM patients and 1-year survival rates in selected groups of patients.
Open AccessMetastatic Uveal Melanoma: Treatment Strategies and Survival—Results from the Dutch Melanoma Treatment Registry
Uveal melanoma (UM) is the most common primary intraocular tumor in adults. Up to 50% of UM patients will develop metastases. We present data of 175 metastatic UM patients diagnosed in the Netherlands between July 2012 and March 2018. In our cohort, elevated lactate dehydrogenase level (LDH) is an important factor associated with poorer survival (Hazard Ratio (HR) 9.0, 95% Confidence Interval (CI) 5.63–14.35), and the presence of liver metastases is negatively associated with survival (HR 2.09, 95%CI 1.07–4.08). We used data from the nation-wide Dutch Melanoma Treatment Registry (DMTR) providing a complete overview of the location of metastases at time of stage IV disease. In 154 (88%) patients, the liver was affected, and only 3 patients were reported to have brain metastases. In 63 (36%) patients, mutation analysis was performed, showing a GNA11 mutation in 28.6% and a GNAQ mutation in 49.2% of the analyzed patients. In the absence of standard care of treatment options, metastatic UM patients are often directed to clinical trials. Patients participating in clinical trials are often subject to selection and usually do not represent the entire metastatic UM population. By using our nation-wide cohort, we are able to describe real-life treatment choices made in metastatic UM patients and 1-year survival rates in selected groups of patients.